Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Kazumichi Kawakubo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8979-9474; OpenAlex author ID A5048055102. Sources: OpenAlex.

Their work

Papers
23 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 5 papers · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: none · 2026: 2 papers

Papers 23

  1. A Case With Longitudinal Changes in Apolipoprotein A2 Isoform Indices Associated With CA19-9 and MRI Findings Until Pancreatic Cancer Development. Co-author DOI 10.1111/jgh.70857↗
  2. Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDAC Co-author DOI 10.64898/2026.03.16.711738↗
  3. Clinical significance of dispersion imaging by shear wave elastography in the treatment and diagnosis of pancreatic cancer. Co-author DOI 10.1111/jgh.16143↗
  4. Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. Co-author DOI 10.1007/s00535-022-01915-2↗
  5. Correction to: Epigenetic regulation of pancreatic adenocarcinoma in the era of cancer immunotherapy. Co-author DOI 10.1007/s00535-022-01922-3↗
  6. Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration-Derived Samples. Co-author DOI 10.1097/mpa.0000000000002028↗
  7. Trial protocol: a randomised controlled trial to verify the non-inferiority of a partially covered self-expandable metal stent to an uncovered self-expandable … First author DOI 10.1136/bmjopen-2020-045698↗
  8. A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancr… Co-author DOI 10.5009/gnl19302↗
  9. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis. Co-author DOI 10.1016/j.pan.2019.04.007↗
  10. Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis. Co-author DOI 10.1111/jgh.14088↗
  11. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Co-author DOI 10.21037/jgo.2017.02.02↗
  12. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  13. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  14. Is intraductal papillary mucinous neoplasm of the pancreas just a precursor or identical with pancreatic ductal adenocarcinoma? Co-author DOI 10.1038/ajg.2013.468↗
  15. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  16. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  17. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  18. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Co-author DOI 10.1097/mpa.0b013e31825de678↗
  19. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  20. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  21. Simultaneous Duodenal Metal Stent Placement and EUS-Guided Choledochoduodenostomy for Unresectable Pancreatic Cancer. Co-author DOI 10.5009/gnl.2012.6.3.399↗
  22. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  23. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masaki Kuwatani · 9 shared papers, 2014–2026 · strength 1.20
  2. Naoya Sakamoto · 8 shared papers, 2014–2026 · strength 1.02
  3. Ryo Sugiura · 3 shared papers, 2018–2026 · strength 0.53
  4. Carlos Fernández-del Castillo · 2 shared papers, 2022 · strength 0.52
  5. Andrew Scott Liss · 2 shared papers, 2022 · strength 0.52
  6. Shin Kato · 4 shared papers, 2018–2023 · strength 0.47
  7. Hiroyuki Isayama · 12 shared papers, 2011–2021 · strength 0.43
  8. Kazuhiko Koike · 12 shared papers, 2011–2021 · strength 0.43
  9. Yousuke Nakai · 12 shared papers, 2011–2021 · strength 0.43
  10. Yasuyuki Kawamoto · 3 shared papers, 2017–2026 · strength 0.36
  11. Ayumi Kashiro · 1 shared paper, 2026 · strength 0.33
  12. Kazufumi Honda · 1 shared paper, 2026 · strength 0.33
  13. Minoru Tada · 11 shared papers, 2011–2015 · strength 0.30
  14. Hirofumi Kogure · 11 shared papers, 2011–2015 · strength 0.30
  15. Naoki Sasahira · 11 shared papers, 2011–2015 · strength 0.30
  16. Kazuaki Harada · 2 shared papers, 2022–2026 · strength 0.30
  17. Yunosuke Takishin · 2 shared papers, 2022–2023 · strength 0.28
  18. Suguru Mizuno · 10 shared papers, 2011–2015 · strength 0.27
  19. Masahiro Itonaga · 2 shared papers, 2021 · strength 0.24
  20. Akio Katanuma · 2 shared papers, 2021 · strength 0.24
  21. Hideaki Ijichi · 8 shared papers, 2012–2015 · strength 0.23
  22. Takashi Sasaki · 8 shared papers, 2011–2015 · strength 0.22
  23. Koji Miyabayashi · 7 shared papers, 2012–2015 · strength 0.20
  24. Dai Mohri · 7 shared papers, 2011–2015 · strength 0.19
  25. Naminatsu Takahara · 7 shared papers, 2011–2015 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.